Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
Sarah JenkinsWei ZhangSeth M SteinbergDarryl NousomeNicole HoustonXiaolin WuTerri S ArmstrongEric BurtonDeeDee K SmartRitu ShahCody J PeerBrett MozarskyOluwatobi ArisaWilliam Douglas FiggTito R MendozaElizabeth VeraPriscilla Kaliopi BrastianosScott L CarterMark R GilbertCarey K AndersCaitriona CahirCarol TweedKaren Lisa SmithImran KhanStanley LipkowitzPatricia S SteegAlexandra S ZimmerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Metronomic TMZ in combination with standard dose T-DM1 shows low-grade toxicity and potential activity in secondary prevention of HER2+ brain metastases.